STEM and the Children’s Hospital of Orange County (“CHOC Children’s”) have entered into an agreement that provides CHOC Children’s with a royalty-free research license to certain of StemCells’ patents. This license authorizes CHOC Children’s to proliferate, maintain and use human neural stem cells for non-commercial purposes. Read more…
Synthetic biology can be used to make nonpolluting fuel, instant vaccines against new diseases and in-expensive medicines, but it will take time, collaboration and a nurturing regulatory environment and scientists. Read more…
A live diagnostic follow-up on a patient enrolled in the APOLLO study was performed and broadcast during the Euro PCR conference on 5/28/10 with this (single patient) outcome demonstrating sustained and further improvements at 18 months; in particular, improvements in infarct size and heart function. Read more…
Stem cells from the amniotic sac that surrounds a fetus may someday be used to repair damage caused by a heart attack. The work, so far only conducted in animals, raises the possibility of a non-controversial source of stem cells to treat not only heart disease but also many other conditions. Read more…
Interim results from ASTM’s US Phase 2b RESTORE-CLI trial will be presented by the principal investigator, Richard J. Powell, MD, section chief of vascular surgery at the Dartmouth-Hitchcock Medical Center in Lebanon, NH at the 2010 Vascular Annual Meeting on 6/11/10 in Boston, MA. Read more…
Founder and Director of Research, Henry McCusker enters his tenth (10) year at Scimitar Equity with past experience in sell-side analysis, buy-side management, corporate management and due diligence.
I started this blog to add commentary, update news flow and insightful opinions that are intelligent, fit to print and SEC compliant.